149 related articles for article (PubMed ID: 32142598)
21. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.
Hirano M; Maeda K; Shitara Y; Sugiyama Y
J Pharmacol Exp Ther; 2004 Oct; 311(1):139-46. PubMed ID: 15159445
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
Takeuchi K; Sugiura T; Umeda S; Matsubara K; Horikawa M; Nakamichi N; Silver DL; Ishiwata N; Kato Y
Drug Metab Dispos; 2011 Jun; 39(6):1088-96. PubMed ID: 21422191
[TBL] [Abstract][Full Text] [Related]
23. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
24. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin.
Lee HI; Choi CI; Sa JH; Lee YJ; Bae JW; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):981-5. PubMed ID: 25138679
[TBL] [Abstract][Full Text] [Related]
26. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.
Gosho M; Tanahashi M; Hounslow N; Teramoto T
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):635-46. PubMed ID: 26104032
[TBL] [Abstract][Full Text] [Related]
27. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
Corsini A; Ceska R
Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
[TBL] [Abstract][Full Text] [Related]
28. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
Wen J; Xiong Y
J Clin Pharm Ther; 2010 Feb; 35(1):99-104. PubMed ID: 20175818
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
[TBL] [Abstract][Full Text] [Related]
30. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
31. [Prediction of the pharmacokinetic drug-drug interaction of pravastatin and pitavastatin with cyclosporine by a digital liver model based on metabolism and transporter].
Yin XF; Lin ZQ; Yang J
Yao Xue Xue Bao; 2011 Sep; 46(9):1108-16. PubMed ID: 22121784
[TBL] [Abstract][Full Text] [Related]
32. Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: a pharmacokinetic study.
Maddela R; Gajula R; Pilli NR; Siddiraju S; Maddela S; Makula A
J Pharm Biomed Anal; 2014 Sep; 98():68-73. PubMed ID: 24887483
[TBL] [Abstract][Full Text] [Related]
33. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
[TBL] [Abstract][Full Text] [Related]
34. Investigations of hydrazine cleavage of eltrombopag in humans.
Deng Y; Rogers M; Sychterz C; Talley K; Qian Y; Bershas D; Ho M; Shi W; Chen EP; Serabjit-Singh C; Gorycki PD
Drug Metab Dispos; 2011 Sep; 39(9):1747-54. PubMed ID: 21646438
[TBL] [Abstract][Full Text] [Related]
35. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization.
Fujino H; Yamada I; Shimada S; Yoneda M; Kojima J
Xenobiotica; 2003 Jan; 33(1):27-41. PubMed ID: 12519692
[TBL] [Abstract][Full Text] [Related]
36. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.
Deng Y; Madatian A; Wire MB; Bowen C; Park JW; Williams D; Peng B; Schubert E; Gorycki F; Levy M; Gorycki PD
Drug Metab Dispos; 2011 Sep; 39(9):1734-46. PubMed ID: 21646437
[TBL] [Abstract][Full Text] [Related]
37. Pre-incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide.
Takahashi T; Ohtsuka T; Uno Y; Utoh M; Yamazaki H; Kume T
Biopharm Drug Dispos; 2016 Nov; 37(8):479-490. PubMed ID: 27603548
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.
Jung JA; Noh YH; Jin S; Kim MJ; Kim YH; Jung JA; Lim HS; Bae KS
Clin Ther; 2012 Apr; 34(4):958-65. PubMed ID: 22410289
[TBL] [Abstract][Full Text] [Related]
39. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Takekoshi N; Saito Y
Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
[TBL] [Abstract][Full Text] [Related]
40. Pitavastatin - pharmacological profile from early phase studies.
Catapano AL
Atheroscler Suppl; 2010 Dec; 11(3):3-7. PubMed ID: 21193152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
